Multiple Sclerosis
"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Descriptor ID |
D009103
|
MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in UAMS Profiles by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 1 | 1 | 2 | 2023 | 1 | 0 | 1 | 2022 | 6 | 0 | 6 | 2021 | 8 | 0 | 8 | 2020 | 1 | 0 | 1 | 2019 | 5 | 1 | 6 | 2018 | 0 | 1 | 1 | 2017 | 1 | 0 | 1 | 2016 | 2 | 0 | 2 | 2013 | 3 | 0 | 3 | 2012 | 2 | 0 | 2 | 2011 | 1 | 0 | 1 | 2009 | 2 | 1 | 3 | 2008 | 1 | 0 | 1 | 2007 | 0 | 1 | 1 | 2006 | 1 | 1 | 2 | 2005 | 3 | 0 | 3 | 2004 | 1 | 1 | 2 | 2003 | 4 | 0 | 4 | 2002 | 2 | 0 | 2 | 2000 | 0 | 1 | 1 | 1994 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles over the past ten years.
-
Duque C, Mahinrad S, Sedaghat S, Higgins J, Milstead A, Sargento-Freitas J, Balabanov R, Cohen B, Sorond FA. Cerebrovascular hemodynamics association with brain structure and function in Multiple Sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105882.
-
Ashrafzadeh-Kian S, Figdore D, Larson B, Deters R, Abou-Diwan C, Bornhorst J, Algeciras-Schimnich A. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays. Clin Chim Acta. 2024 Jul 15; 561:119817.
-
Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, Karabudak R, Yamout BI, Khoury SJ, Terzi M, Boz C, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Patti F, Altintas A, Mrabet S, Gouider R, Inshasi J, Shaygannejad V, Eichau S, Ward WL, Butzkueven H. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study. Neurology. 2024 Apr 09; 102(7):e208114.
-
Harrison TC, Blozis SA, Stuifbergen AK, Becker H. Longitudinal Effects of Sex, Aging, and Multiple Sclerosis Diagnosis on Function. Nurs Res. 2023 Jul-Aug 01; 72(4):281-291.
-
Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord. 2023 Jul; 75:104763.
-
Wotipka E, Mortensen P, Charoenkijkajorn C, Pakravan M, Lee AG. Apraxia of lid opening in multiple sclerosis. Can J Ophthalmol. 2023 06; 58(3):e139-e141.
-
Sharma K, Tolaymat S, Yu H, Elkhooly M, Jaiswal S, Jena A, Kakara M, Sriwastava S. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. J Neurol Sci. 2022 12 15; 443:120459.
-
Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord. 2022 Dec; 68:104125.
-
Feizi P, Sharma K, Pasham SR, Nirwan L, Joseph J, Jaiswal S, Sriwastava S. Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. J Neuroimmunol. 2022 10 15; 371:577939.
-
Sidarous GK, Roy AM, Sasapu A. Acquired Hemophilia A in a Patient With Multiple Sclerosis. Perm J. 2022 06 29; 26(2):153-157.
-
Sharma K, Chaudhary D, Beard K, Srivastava S, Khalid SH, Sriwastava S. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Mult Scler Relat Disord. 2022 Mar; 59:103675.
-
Pike AR, James GA, Drew PD, Archer RL. Neuroimaging predictors of longitudinal disability and cognition outcomes in multiple sclerosis patients: A systematic review and meta-analysis. Mult Scler Relat Disord. 2022 Jan; 57:103452.
-
Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, Khalid SH, Lisak RP. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol. 2022 Mar; 269(3):1678-1687.
-
Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021 Nov 15; 430:120034.
-
Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021 11 15; 360:577721.
-
Chauhan MZ, Chacko JG, Phillips PH, Siddiqui MZ, Uwaydat SH. Association of Acute Zonal Occult Outer Retinopathy With Multiple Sclerosis: A Report of 2 Cases. J Neuroophthalmol. 2022 03 01; 42(1):e377-e380.
-
Podury S, Khan E, Tandon M, Jaiswal S, Sriwastava S. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination. J Clin Neurosci. 2021 Aug; 90:132-134.
-
Chacko JA, Strati P, Stout PW, Archer RL, Baltz BP, Chacko JG. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Apr; 49:102776.
-
Erramuzpe A, Schurr R, Yeatman JD, Gotlib IH, Sacchet MD, Travis KE, Feldman HM, Mezer AA. A Comparison of Quantitative R1 and Cortical Thickness in Identifying Age, Lifespan Dynamics, and Disease States of the Human Cortex. Cereb Cortex. 2021 01 05; 31(2):1211-1226.
-
Kovvuru S, Nalleballe K, Onteddu SR, Sharma R, Jasti M, Kapoor N, Veerapaneni K, Yadala S, Dandu V, Archer R, Nowak RJ, Roy B. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021 01 15; 420:117230.
-
Vattoth S, Kadam GH, Gaddikeri S. Revised McDonald Criteria, MAGNIMS Consensus and Other Relevant Guidelines for Diagnosis and Follow Up of MS: What Radiologists Need to Know? Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):389-400.
-
Lewis HS, Willis E, Veerapandiyan A. Charcot-Marie-Tooth Disease Type 4J and Multiple Sclerosis. J Clin Neuromuscul Dis. 2019 Dec; 21(2):117-118.
-
Sriwastava S, Yarraguntla K, Zutshi D, Basha MM, Bernitsas E, Marawar R. Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures. J Neurol Sci. 2019 Nov 15; 406:116482.
-
Neuhouser A, Sanders R, Burks JR, Chacko J. Retinal Findings in Two Patients With Tumefactive Multiple Sclerosis. J Neuroophthalmol. 2019 09; 39(3):399-400.
-
Palani CD, Fouda AY, Liu F, Xu Z, Mohamed E, Giri S, Smith SB, Caldwell RB, Narayanan SP. Deletion of Arginase 2 Ameliorates Retinal Neurodegeneration in a Mouse Model of Multiple Sclerosis. Mol Neurobiol. 2019 Dec; 56(12):8589-8602.
-
Quinlan ND, Chen DQ, Werner BC, Barnes CL, Browne JA. Patients With Multiple Sclerosis are at Increased Risk for Postoperative Complications Following Total Hip and Knee Arthroplasty. J Arthroplasty. 2019 Aug; 34(8):1606-1610.
-
Cho JJ, Xu Z, Parthasarathy U, Drashansky TT, Helm EY, Zuniga AN, Lorentsen KJ, Mansouri S, Cho JY, Edelmann MJ, Duong DM, Gehring T, Seeholzer T, Krappmann D, Uddin MN, Califano D, Wang RL, Jin L, Li H, Lv D, Zhou D, Zhou L, Avram D. Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. Nat Commun. 2019 02 11; 10(1):701.
-
Cohen B, Balcells C, Hotchkiss B, Aggarwal K, Karaa A. A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008-2015. Orphanet J Rare Dis. 2018 11 22; 13(1):210.
-
Mock DM. Biotin: From Nutrition to Therapeutics. J Nutr. 2017 08; 147(8):1487-1492.
-
Lieben CK, Blokland A, Deutz NE, Jansen W, Han G, Hupperts RM. Intake of tryptophan-enriched whey protein acutely enhances recall of positive loaded words in patients with multiple sclerosis. Clin Nutr. 2018 02; 37(1):321-328.
-
Torres C, Hogan M, Patro S, Chakraborty S, Nguyen T, Thornhill R, Freedman M, Bussiere M, Dabirzadeh H, Schwarz BA, Belanger S, Legault-Kingstone L, Schweitzer M, Lum C. Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant? Eur Radiol. 2017 Jan; 27(1):239-246.
-
Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther. 2016 06; 16(6):827-839.
-
Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol. 2016; 12(3):327-44.
-
Stuifbergen AK, Blozis S, Becker H, Harrison T, Kullberg V. Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual?follow-up. Disabil Health J. 2016 07; 9(3):472-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|